Bevacizumab (BV) is an active drug of anti-angiogenesis for colorectal cancer (CRC). NCCN and Japanese Guideline both recommend to use BV at 1st-line chemotherapy for CRC. Some reports suggested survival benefit of using BV beyond progression (BBP). We analyzed CRC patients with BBP retrospectively.Patients
From April 2007, 256 patients were recieved chemotherapy at our institute, 136 patients were treated with BV at 1st line, and BBP were 29 patients.Results
Age: 40–74 (median 65) years. Male 23, Female 6. Regimen with BBP was FOLFOX 10, CapeOX 3, FOLFIRI 16. Tumor responses were seen in 4 patients of 28 patients. No perforation was observed during BBP chemotherapy. More than Grade3 nonhematological toxicity was one patient with nausea and anorexia due to FOLFIRI. Of 20 patients with progression after BBP, 3rd-line chemotherapy were delivered in 10 patients. Overall survival time of 136 patients with BV was 983 days, and PFS of BBP was 123 days.Conclusion
There was no serious toxicity due to BV in second ine chemotherapy with BBP.